The impact of modulator therapy on the Pseudomonas aeruginosa cystic fibrosis lung transcriptome.
6 affiliations
- 1School of Biological Sciences and Center for Microbial Dynamics and Infection, Georgia Institute of Technology, Atlanta, GA 30332.
- 2Emory-Children's Cystic Fibrosis Center, Atlanta, GA 30322.
- 3Department of Microbiology, University of Washington School of Medicine, Seattle, WA 98195.
- 4Department of Medicine, University of Washington School of Medicine, Seattle, WA 98195.
- 5National Referral Center for Adult Cystic Fibrosis, National Referral Center for Adult Cystic Fibrosis, St. Vincent's University Hospital, Dublin D04 T6F4, Ireland.
- 6University College Dublin School of Medicine, Dublin D04 C7X2, Ireland.
Abstract
Chronic lung infection with Pseudomonas aeruginosa is a major complication of cystic fibrosis (CF), contributing to lung function decline and increased morbidity and mortality. Laboratory models are used to study CF infections, but their relevance depends on how accurately they reproduce microbial physiology during human infection. We previously developed a framework that uses bacterial gene expression in human infections to quantify model accuracy. Here, we applied this framework to determine how a major therapeutic intervention impacts P. aeruginosa physiology in the lungs of people with CF (pwCF) and to develop and evaluate refined preclinical models. We focused on elexacaftor/tezacaftor/ivacaftor (ETI), a highly effective CFTR modulator therapy that has improved outcomes for pwCF. However, evidence indicates that P. aeruginosa lung infections persist despite ETI therapy. Analysis of P. aeruginosa transcriptomes from human sputum collected before and after ETI initiation revealed minimal changes in gene expression, indicating that the CF airway continues to support a similar bacterial transcriptional state despite therapy. We then evaluated how strain selection, zinc limitation, and polymicrobial coculture influence the ability of laboratory models to recapitulate P. aeruginosa gene expression in human CF sputum. Growth of CF clinical isolates in zinc-limited synthetic CF sputum medium produced the most accurate model, whereas population-based cultures and coculture with Staphylococcus aureus had limited effects. These findings show that ETI therapy has little impact on the conserved P. aeruginosa transcriptional state in human CF sputum and that refined sputum-like models remain useful for studying persistent infection in the postmodulator era.
Related
- Expression of ExsA in trans Confers Type III Secretion System-Dependent Cytotoxicity on Noncytotoxic Pseudomonas aeruginosa Cystic Fibrosis Isolates
- Cell Death of Human Polymorphonuclear Neutrophils Induced by a Pseudomonas aeruginosa Cystic Fibrosis Isolate Requires a Functional Type III Secretion System
- Pseudomonas aeruginosa Cystic Fibrosis Isolates Induce Rapid, Type III Secretion-Dependent, but ExoU-Independent, Oncosis of Macrophages and Polymorphonuclear Neutrophils
- Role of manganese superoxide dismutase in a mucoid isolate of Pseudomonas aeruginosa: adaptation to oxidative stress
- Mechanical compression activates cAMP signaling in Pseudomonas aeruginosa
BibTeX
@article{letizia2026impact,
title = {{The impact of modulator therapy on the Pseudomonas aeruginosa cystic fibrosis lung transcriptome.}},
author = {Morgana Letizia and Lauren E Whiteley and Frances L Diggle and Angela N Davis and Sarah J Morgan and Brenda Grogan and John Baugh and Edward F McKone and Pradeep K Singh and Marvin Whiteley},
journal = {Proceedings of the National Academy of Sciences of the United States of America},
year = {2026},
month = oct,
doi = {10.1073/pnas.2622466123},
url = {https://europepmc.org/article/MED/42879475},
note = {CC BY},
}
RIS
TY - JOUR
TI - The impact of modulator therapy on the Pseudomonas aeruginosa cystic fibrosis lung transcriptome.
AU - Morgana Letizia
AU - Lauren E Whiteley
AU - Frances L Diggle
AU - Angela N Davis
AU - Sarah J Morgan
AU - Brenda Grogan
AU - John Baugh
AU - Edward F McKone
AU - Pradeep K Singh
AU - Marvin Whiteley
PY - 2026
DA - 2026/10/15
JO - Proceedings of the National Academy of Sciences of the United States of America
DO - 10.1073/pnas.2622466123
UR - https://europepmc.org/article/MED/42879475
AB - Chronic lung infection with Pseudomonas aeruginosa is a major complication of cystic fibrosis (CF), contributing to lung function decline and increased morbidity and mortality. Laboratory models are used to study CF infections, but their relevance depends on how accurately they reproduce microbial physiology during human infection. We previously developed a framework that uses bacterial gene expression in human infections to quantify model accuracy. Here, we applied this framework to determine how a major therapeutic intervention impacts P. aeruginosa physiology in the lungs of people with CF (pwCF) and to develop and evaluate refined preclinical models. We focused on elexacaftor/tezacaftor/ivacaftor (ETI), a highly effective CFTR modulator therapy that has improved outcomes for pwCF. However, evidence indicates that P. aeruginosa lung infections persist despite ETI therapy. Analysis of P. aeruginosa transcriptomes from human sputum collected before and after ETI initiation revealed minimal changes in gene expression, indicating that the CF airway continues to support a similar bacterial transcriptional state despite therapy. We then evaluated how strain selection, zinc limitation, and polymicrobial coculture influence the ability of laboratory models to recapitulate P. aeruginosa gene expression in human CF sputum. Growth of CF clinical isolates in zinc-limited synthetic CF sputum medium produced the most accurate model, whereas population-based cultures and coculture with Staphylococcus aureus had limited effects. These findings show that ETI therapy has little impact on the conserved P. aeruginosa transcriptional state in human CF sputum and that refined sputum-like models remain useful for studying persistent infection in the postmodulator era.
SN - 0027-8424
SN - 1091-6490
ER -